These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 2243136)
1. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. Christen RD; Hom DK; Porter DC; Andrews PA; MacLeod CL; Hafstrom L; Howell SB J Clin Invest; 1990 Nov; 86(5):1632-40. PubMed ID: 2243136 [TBL] [Abstract][Full Text] [Related]
2. Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor-alpha. Isonishi S; Jekunen AP; Hom DK; Eastman A; Edelstein PS; Thiebaut FB; Christen RD; Howell SB J Clin Invest; 1992 Oct; 90(4):1436-42. PubMed ID: 1401076 [TBL] [Abstract][Full Text] [Related]
3. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Gründker C; Völker P; Emons G Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684 [TBL] [Abstract][Full Text] [Related]
4. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Frankel A; Mills GB Clin Cancer Res; 1996 Aug; 2(8):1307-13. PubMed ID: 9816301 [TBL] [Abstract][Full Text] [Related]
5. [Effects of mifepristone on the proliferation, apoptosis, and cis-platinum (DDP) sensitivity of chemo-resistant human ovarian cancer cells]. Wang G; Zheng WT; Xiao P; Li XJ; Lin TC; Li GY Ai Zheng; 2004 Apr; 23(4):406-11. PubMed ID: 15087028 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer. Kalli KR; Bradley SV; Fuchshuber S; Conover CA Gynecol Oncol; 2004 Sep; 94(3):705-12. PubMed ID: 15350362 [TBL] [Abstract][Full Text] [Related]
7. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522 [TBL] [Abstract][Full Text] [Related]
8. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Chan JK; Pham H; You XJ; Cloven NG; Burger RA; Rose GS; Van Nostrand K; Korc M; Disaia PJ; Fan H Cancer Res; 2005 Apr; 65(8):3243-8. PubMed ID: 15833856 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Holzer AK; Katano K; Klomp LW; Howell SB Clin Cancer Res; 2004 Oct; 10(19):6744-9. PubMed ID: 15475465 [TBL] [Abstract][Full Text] [Related]
10. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model. Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326 [TBL] [Abstract][Full Text] [Related]
11. [Enhancement of antitumor effect of cisplatin on human ovarian cancer by cyclosporin A in vitro and in vivo]. Zhou Y; Chen H; Yang Q Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):25-8. PubMed ID: 8758815 [TBL] [Abstract][Full Text] [Related]
12. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line. Du P; Zhang X; Liu H; Chen L DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922 [TBL] [Abstract][Full Text] [Related]
13. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Eicke N; Günthert AR; Emons G; Gründker C Int J Oncol; 2006 Nov; 29(5):1223-9. PubMed ID: 17016655 [TBL] [Abstract][Full Text] [Related]
14. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764 [TBL] [Abstract][Full Text] [Related]
15. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP]. Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863 [TBL] [Abstract][Full Text] [Related]
16. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890 [TBL] [Abstract][Full Text] [Related]
17. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. Reimer D; Hubalek M; Riedle S; Skvortsov S; Erdel M; Concin N; Fiegl H; Müller-Holzner E; Marth C; Illmensee K; Altevogt P; Zeimet AG Cancer Res; 2010 Jun; 70(11):4613-23. PubMed ID: 20460525 [TBL] [Abstract][Full Text] [Related]
18. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion. Andrews PA; Murphy MP; Howell SB Mol Pharmacol; 1986 Dec; 30(6):643-50. PubMed ID: 3785141 [TBL] [Abstract][Full Text] [Related]
20. [Effects of recombinant human interleukin-24 alone and in combination with cisplatin on the growth of ovarian cancer cells in vitro]. Wang S; Guo J; Tang Y; Zheng R; Song M; Sun W Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jan; 30(1):33-6. PubMed ID: 24405596 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]